OR WAIT null SECS
Sustained IOP Reduction With iDose TR, With Steven R. Sarkisian, Jr., MD
Travoprost intracameral implant significantly reduces intraocular pressure and medication use in patients with glaucoma over three years.
Administration of a travoprost intracameral implant, 75 mcg (iDose® TR), led to a significant reduction in both intraocular pressure (IOP) and IOP-lowering medication burden at 36 months among individuals with open-angle glaucoma or ocular hypertension.1
Presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, the mean IOP reductions hit 6.2 mmHg and 7.0 mmHg for the travoprost intracameral implant versus timolol, while a significantly higher number of eyes receiving the implant were on the same or fewer IOP-lowering medications.
“Basically, 80% of people were medication-free, and there was a significant drop in pressure that was sustainable out to three years in this particular data set from the clinical trial comparing timolol and the iDoseTR,” investigator Steven R. Sarkisian, Jr., MD, founder and chief executive officer of Oklahoma Eye Surgeons, told HCPLive. “It demonstrated a 6.5 IOP mmHg pressure at a year and then maintained that 6-6.5 drop in pressure at 36 months.”
The study population comprised individuals with open-angle glaucoma or ocular hypertension from the prospective, randomized, multicenter Phase 3 trial, GC-010. Participants were treated with 0–3 IOP-lowering medications before the study, with a baseline unmedicated mean diurnal IOP ≥21 mmHg and IOP ≤36 at each baseline diurnal timepoint.
Participants received a slow-eluting travoprost intracameral implant (n = 197) or timolol 0.5% BID eyedrops (n = 193). Investigators also evaluated a fast-eluting travoprost implant (n = 200) in the trial.
An analysis measured the IOP-lowering treatment effect and the percentage of eyes in the commercially approved travoprost intracameral implant group, compared with the timolol group on the same or lower number of IOP-lowering medications. Analysis occurred at Months 12, 18, 24, 30, and 36, compared with the pre-study period.
Upon analysis, the mean IOP reductions for the travoprost intracameral implant and timolol cohorts were 6.5/7.0 mmHg at 12 months, 6.4/7.0 mmHg at 18 months, and 6.3/7.0 mmHg at 24 months, followed by 6.3/7.0 mmHg at 30 months, and 6.2/7.0 mmHg at 36 months, respectively. Reductions in all visits for both cohorts were statistically significant from baseline (P <.0001).
Further analysis found a significantly higher number of eyes receiving the travoprost intracameral implant vs timolol were on the same or fewer IOP-lowering medications at 12 months (92% vs. 70%; P <.0001), 18 months (84% vs. 68%; P =.0004), 24 months (80% vs 65%; P =.0042), 30 months (76% vs. 64%; P =.0282), and 36 months (71% vs. 59%; P =.0338), compared with the pre-study period.
“I think the iDose TR fits very nicely as a second-line therapy, and I know that it's going to be hard to shake the paradigm of eye drops not being second-line therapy,” Sarkisian told HCPLive. “As we see this unfold over time and as insurance coverage improves, where it's not just Medicare patients that are getting reimbursed for this, I think that we're going to see a lot of eyes that are going to be be saved from blindness because they're going to have perfect compliance with the medication.”
Relevant disclosures for Sarkisian include AbbVie, Allergan, Bausch & Lomb, Glaukos, Novartis, Ocular Therapeutix, and others.
